The Discovery of Penicillin

Photo: www.kaboompics.com / Pexels
Penicillin is the world's first antibiotic, discovered by Alexander Fleming in London in September 1928 when a mold contaminated one of his bacterial cultures and dissolved the bacteria around it. Fleming identified the mold as Penicillium notatum and named the antibacterial substance penicillin. Twelve years later, Howard Florey, Ernst Chain, and Norman Heatley at Oxford University turned that observation into a medicine that would save an estimated 200 million lives.
The Petri Dish Accident That Fleming Almost Threw Away
In September 1928, Alexander Fleming returned from a summer holiday to find his laboratory at St. Mary's Hospital in London in disarray. He had left Petri dishes of Staphylococcus bacteria stacked on his bench before leaving, and mold had invaded one of them. This was not unusual — Fleming's lab was famously untidy. What was unusual was what he noticed before tossing the dish into disinfectant.
Around the blue-green mold colony, the bacterial growth had dissolved. There was a clear halo where bacteria should have been. Fleming stopped. He recognized this as the action of some antibacterial substance diffusing outward from the mold. He identified the contaminant as Penicillium notatum — likely blown in through an open window from a mycology lab one floor below — and named the active substance penicillin.
Antibiotic — a substance produced by one microorganism that kills or inhibits the growth of another microorganism.
Fleming published his findings in the British Journal of Experimental Pathology in June 1929. He noted that the substance inhibited a wide range of gram-positive bacteria and appeared non-toxic to animals in preliminary tests. But he could not purify or concentrate it. Penicillin degraded rapidly, and Fleming lacked the chemical expertise to stabilize it. His 1929 paper attracted little attention. For the next decade, penicillin sat largely dormant in the scientific literature.
Source: Fleming, A. (1929). "On the Antibacterial Action of Cultures of a Penicillium" — British Journal of Experimental Pathology, Vol. 10, pp. 226–236. The founding paper of antibiotic therapy.
It is worth noting that Fleming was not the first to observe that penicillin molds could kill bacteria. French physician Ernest Duchesne demonstrated the antibacterial effect of Penicillium glaucum in his 1897 thesis, but his work was forgotten. John Tyndall had noted similar mold-versus-bacteria competition in 1875. Fleming's contribution was not the initial observation but the decision to investigate it rigorously and name the active substance.
How Penicillin Actually Kills Bacteria
Penicillin's mechanism is elegant. Bacterial cells are surrounded by a rigid cell wall made of a mesh-like polymer called peptidoglycan — a lattice of sugar chains crosslinked by short peptide bridges. This wall is under constant osmotic pressure, like a water balloon held together by its casing. Without the wall, the bacterium swells and bursts.
Bacteria continuously rebuild and repair their cell walls as they grow and divide. A family of enzymes called transpeptidases (also known as penicillin-binding proteins, or PBPs) catalyze the crosslinking step — the final stitching of the peptidoglycan mesh. Penicillin mimics the substrate these enzymes normally act on. It binds irreversibly to the active site of the transpeptidase, blocking it permanently.
The result is that growing bacteria can no longer complete their cell wall synthesis. They keep trying to grow and divide, but the new wall material is not properly crosslinked. The wall weakens, the osmotic pressure tears it apart, and the cell lyses — ruptures and dies. Penicillin only kills actively dividing bacteria; dormant cells are unaffected. This is why completing a course of antibiotics matters: resting bacteria that survive the initial dose can resume dividing once the drug is gone.
Source: Tipper, D.J. and Strominger, J.L. (1965). "Mechanism of action of penicillins" — PNAS, Vol. 54, pp. 1133–1141. The landmark paper establishing the transpeptidase inhibition model.
Penicillin is bactericidal — it kills bacteria — rather than bacteriostatic — which merely inhibits growth. It is also selectively toxic: human cells have no peptidoglycan cell walls, so penicillin cannot disrupt them by this mechanism. This selectivity is why Fleming's early animal tests showed low toxicity. The drug hits bacteria and spares mammalian cells.
This is analogous to removing the load-bearing bolts from a structure that is actively under construction. The building does not collapse immediately, but as new sections go up with no way to anchor them, the whole thing eventually gives way under its own weight.
The Oxford Team: From Curiosity to Cure
The transformation of penicillin from an interesting laboratory observation into a practical medicine happened not in Fleming's lab but in the Sir William Dunn School of Pathology at Oxford University, and it happened because of a 1939 literature search.
Howard Florey, the Australian-born professor who directed the school, tasked biochemist Ernst Chain with surveying the scientific literature on antibacterial substances produced by microorganisms. Chain found Fleming's 1929 paper and was struck by the potential. Florey secured funding from the Rockefeller Foundation — critically, US funding, because wartime Britain had almost none to spare — and the team began trying to purify penicillin in 1939.
Ernst Chain — German-Jewish biochemist who fled Nazi Germany in 1933 and joined Oxford, where he solved the chemical structure and purification of penicillin.
The technical problem was severe. Penicillin broke down rapidly at room temperature, was present in Penicillium cultures at extremely low concentrations, and had chemical properties that made isolation difficult. Norman Heatley, the team's experimental genius, devised an improvised purification method using back-extraction: dissolving penicillin into ethyl acetate at low pH, then back-extracting it into water at higher pH. He used laboratory glassware, hospital bedpans, milk churns, and improvised equipment he machined himself. The scale of production was nothing the drug industry would recognize — they were making enough to treat one patient at a time.
Source: Heatley, N. (1944). "Penicillin" — Biochemical Journal, describing the improvised production methods at Oxford. National WWII Museum records document the bedpan extraction apparatus.
On May 25, 1940, Florey's team ran their first decisive experiment. Eight mice were infected with a lethal dose of Streptococcus. Four received penicillin injections. By the next morning, the four treated mice were alive; the four controls were dead. Florey reportedly told his wife: "It looks like a miracle."
The first human trial came in January 1941. Albert Alexander, a 43-year-old Oxford police constable, had developed a life-threatening infection — a scratch from a rose bush had spread to his face, scalp, lungs, and eye. He was dying. Florey's team injected him with their entire penicillin stockpile. Alexander improved dramatically within 24 hours. Then the penicillin ran out. The team extracted what they could from Alexander's urine and re-injected it, but they could not produce enough to keep pace with the infection. Alexander died five weeks later. The treatment had worked — the supply had not.
The People: Fleming, Florey, Chain, and the Forgotten Heatley
The history of penicillin involves at least four people whose contributions require separate accounting.
Alexander Fleming identified penicillin and published the 1929 paper that would eventually attract Florey's attention. He had limited chemical expertise and could not purify the substance, but his observation and his decision to investigate it — and to keep a culture of the mold — were the essential starting points. Fleming was a quiet, self-contained man who worked in a cluttered laboratory and often stumbled into important discoveries through careful attention to anomalies. He had previously discovered lysozyme, an antibacterial enzyme in tears and saliva, by a similar process of noticing an unexpected result.
Howard Florey was the organizational and scientific force behind Oxford's penicillin program. He secured funding, managed a large team during wartime, ran the animal studies, and coordinated the eventual push to industrial production. Australian-born, trained at Oxford and Sheffield, he was pragmatic and driven. Florey was reportedly less comfortable with the media attention that came with penicillin's success, and he remained largely outside the public narrative while Fleming became a celebrity.
Ernst Chain solved the chemical problems of extraction and purification. He determined penicillin's beta-lactam structure (a four-membered ring containing nitrogen) and developed methods to concentrate it. His relationship with Florey was professionally productive but personally fractious — Chain felt he deserved more credit and eventually left Oxford for Rome.
Norman Heatley made the industrial-scale production possible through improvised engineering. He was excluded from the 1945 Nobel Prize on the grounds that the prize was for medicine, not chemistry (though Chain was a chemist), or simply because the prize committee limited the award to three people. In 1990, Oxford University awarded Heatley its first honorary Doctorate of Medicine in its 800-year history — recognition long overdue.
Source: Lax, E. (2004). The Mold in Dr. Florey's Coat — Viking Press. The most thorough single-volume account of the Oxford penicillin team and Heatley's role.
WWII Mass Production: Pfizer, Merck, and the American Effort
Florey and Heatley traveled to the United States in July 1941, carrying penicillin cultures in their coat linings (they had sewn the mold into the fabric so it could be recovered if their luggage was lost). They met with officials at the USDA Northern Regional Research Laboratory in Peoria, Illinois, and with pharmaceutical companies including Merck, Pfizer, Squibb, and Lilly.
Several critical advances happened in the United States. The Peoria lab discovered that corn steep liquor — a waste product of corn starch production — dramatically increased penicillin yields when used as a growth medium. A laboratory assistant, Mary Hunt, found a moldy cantaloupe in a local market whose Penicillium chrysogenum strain produced 200 times more penicillin than Fleming's original P. notatum. Further mutation by X-ray and UV treatment of that strain pushed yields higher still.
Pfizer, under John L. Smith, pioneered the deep-tank fermentation process that made industrial production viable. Instead of growing mold on the surface of liquid in thousands of flat vessels — the Oxford method — Pfizer grew it submerged in large agitated tanks. By 1943, Pfizer was producing enough penicillin to treat several hundred patients per month. By D-Day in June 1944, Allied forces had enough penicillin to treat every infected wound. Military surgeons estimated that penicillin reduced death rates from infected battle wounds by 15 percent compared to World War I.
| Year | Milestone | Key Actor |
|---|---|---|
| 1928 | Fleming identifies penicillin from contaminated petri dish | Alexander Fleming, London |
| 1929 | Discovery published in Brit. J. Exp. Pathology | Fleming |
| 1939 | Oxford team begins purification research | Florey, Chain, Heatley |
| 1940 | First mouse experiment confirms therapeutic effect | Oxford team |
| 1941 | First human trial (Albert Alexander) | Oxford team |
| 1941 | Florey and Heatley travel to US for industrial scale-up | Florey, Heatley, USDA Peoria |
| 1943 | Deep-tank fermentation at Pfizer begins large-scale production | Pfizer, John L. Smith |
| 1944 | Sufficient supply for D-Day Allied forces | US pharmaceutical industry |
| 1945 | Nobel Prize in Physiology or Medicine awarded | Fleming, Florey, Chain (Heatley excluded) |
| 1957 | John Sheehan synthesizes penicillin chemically at MIT | MIT |
| 1990 | Oxford awards Heatley honorary Doctorate of Medicine | Oxford University |
Timeline of penicillin's journey from petri dish to industrial medicine — a 16-year process that required contributions from at least a dozen scientists across two continents.
The 1945 Nobel and Its Exclusions
The Nobel Prize in Physiology or Medicine 1945 was awarded jointly to Alexander Fleming, Howard Florey, and Ernst Chain "for the discovery of penicillin and its curative effect in various infectious diseases." The selection was defensible but not uncontroversial.
Fleming received the largest share of public credit partly because his name was attached to the discovery story and partly because he was more media-accessible than the reserved Florey. When penicillin became a household word during WWII, newspapers reported the story as "Fleming discovers wonder drug." Florey, who had actually turned that discovery into a usable drug, was irritated by this characterization and said so publicly.
Chain's exclusion from credit for the chemical work on penicillin's structure was later resolved somewhat by the Nobel — but Heatley received nothing from the committee. His engineering contributions — the improvised purification equipment, the back-extraction method, the cultivation methods he devised — were classified as technical rather than scientific, a distinction that reflects the bias of prize committees toward theoretical insight over practical problem-solving.
Mary Hunt, whose cantaloupe mold strain was responsible for virtually all the penicillin produced in WWII, received no prize and little recognition. The women of the Oxford lab — including Margaret Jennings and Mary Ethel Florey — contributed substantially to the research and appeared in none of the awards.
Source: American Chemical Society (2014). "Alexander Fleming Discovery and Development of Penicillin" — ACS National Historic Chemical Landmarks. Comprehensive sourcing of the Nobel attribution and its critics.
Unintended Consequences: The Antibiotic Resistance Crisis
In his 1945 Nobel lecture, Alexander Fleming issued a warning that was both prescient and largely ignored for decades. He said that if penicillin could be obtained freely in shops, "the ignorant man" might underdose himself, exposing bacteria to sub-lethal concentrations and selecting for resistance. This, he warned, would result in the "education of microbes" to resist the drug.
Fleming was right. Antibiotic resistance is now one of the most serious threats to global public health. The mechanism is evolutionary: a large bacterial population exposed to an antibiotic contains rare individuals with mutations that allow them to survive at low drug concentrations. Those individuals reproduce. Their descendants inherit the resistance. Under the selective pressure of antibiotic use, resistant strains spread.
Antibiotic resistance — the ability of bacteria to survive exposure to an antibiotic that would previously have killed them, acquired through mutation or horizontal gene transfer.
Bacteria have evolved multiple resistance mechanisms against penicillin. The most common is production of beta-lactamase enzymes, which break the beta-lactam ring that is essential to penicillin's activity. Some bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), have modified their penicillin-binding proteins so that the drug cannot bind effectively. Others have evolved pumps that expel antibiotics before they can act.
The WHO estimated in 2019 that antimicrobial resistance directly caused 1.27 million deaths globally and was associated with nearly 5 million deaths (Murray et al., 2022, The Lancet). That figure is projected to rise to 10 million deaths annually by 2050 if resistance trends continue unchecked — a number that would exceed annual cancer mortality.
Much of the resistance problem was accelerated not by human medicine but by agriculture. Approximately 70 percent of medically important antibiotics sold in the United States are used in livestock — not to treat sick animals, but to promote growth and prevent infections in crowded conditions (FDA data, 2017). This creates large reservoirs of antibiotic-selective pressure in environments where resistance can evolve and spread to human pathogens.
Source: Murray, C.J.L. et al. (2022). "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis" — The Lancet, Vol. 399, pp. 629–655. The most authoritative global estimate of resistance mortality.
Where Penicillin Stands Today
Penicillin remains in clinical use — it did not become obsolete, as many who read about resistance assume. Natural penicillin (penicillin G and penicillin V) is still the drug of choice for streptococcal pharyngitis, syphilis caused by Treponema pallidum, and several other infections where resistance has not established itself.
The more significant development is the family of semi-synthetic and synthetic penicillins and related beta-lactam antibiotics that chemists derived from the core structure. Ampicillin, amoxicillin, and piperacillin are all variants of the penicillin scaffold, modified to extend the spectrum or resist specific resistance mechanisms. The cephalosporins, carbapenems, and monobactams are structurally related through the beta-lactam ring. Together this family constitutes the most widely used class of antibiotics in clinical medicine.
John Sheehan at MIT achieved the first total chemical synthesis of penicillin in 1957, which opened the door to producing variants that do not depend on mold fermentation. Sheehan's synthesis also revealed the full chemical structure, confirming Chain and Dorothy Hodgkin's earlier X-ray crystallographic work.
The antibiotic resistance crisis has renewed interest in penicillin's history as a cautionary tale. Several pharmaceutical companies exited antibiotic development in the 1990s and 2000s because the economics were poor — a drug taken for 10 days generates less revenue than one taken for life. This market failure left a dwindling pipeline of new antibiotics at precisely the moment resistance was accelerating. Regulatory and funding changes since 2010, including the GAIN Act in the US and similar European measures, have partially reversed this trend.
Source: Science History Institute (2024). "Howard Walter Florey and Ernst Boris Chain" — biographical entry with extensive sourcing of the commercial and regulatory history of penicillin development.
FAQs
Q: Did Alexander Fleming actually discover penicillin, or just observe it?
A: Fleming observed penicillin's antibacterial effect and named the substance, but he did not purify, characterize, or develop it into a drug. That work was done by Florey, Chain, and Heatley at Oxford a decade later. Fleming's contribution was the seminal observation and the 1929 paper that eventually attracted Florey's attention.
Q: Why did it take 12 years to go from Fleming's discovery to a working drug?
A: Penicillin was chemically unstable and present in mold cultures in extremely low concentrations. Fleming lacked the chemical expertise to purify it. The Oxford team, which included skilled biochemists like Chain and Heatley, had the right combination of skills and also the motivation of WWII urgency and Rockefeller Foundation funding.
Q: Why wasn't Norman Heatley included in the Nobel Prize?
A: The Nobel Prize rules at the time limited the prize to three recipients, and the committee viewed Heatley's contributions as engineering rather than scientific discovery. Oxford University partially recognized this injustice in 1990 by awarding Heatley its first honorary Doctorate of Medicine in its 800-year history.
Q: How does antibiotic resistance develop?
A: When bacteria are exposed to antibiotics, rare individuals with mutations that confer resistance survive and reproduce. Their offspring inherit the resistance genes. Exposure to antibiotics — especially sub-lethal doses, or doses stopped before all bacteria are killed — creates selective pressure that favors resistant strains. Resistance genes can also spread between bacteria via horizontal gene transfer, where one bacterium passes a resistance gene directly to another.
Q: Is penicillin still used today, or has it been replaced?
A: Natural penicillin is still the first-choice treatment for several infections, including streptococcal throat infections and syphilis. Semi-synthetic variants like amoxicillin are among the most prescribed drugs in the world. The penicillin scaffold underlies an entire family of beta-lactam antibiotics that remain the most widely used class in clinical medicine.
Q: How many lives has penicillin saved?
A: Estimates range from 80 million to 200 million lives saved since its introduction in the 1940s. The figure is difficult to calculate precisely because it requires estimating the counterfactual death rate from bacterial infections without antibiotics. Pre-antibiotic mortality from pneumonia, sepsis, and infected wounds provides the baseline.
Read next:
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles

The Invention of the Solar Cell
How Bell Labs' 1954 silicon breakthrough, a 1958 satellite, and a 99.9% price collapse turned sunlight into the world's cheapest source of electricity.

mRNA Vaccines: The Technology That Took 30 Years to Arrive
How Katalin Karikó and Drew Weissman solved the immune rejection problem with mRNA in 2005, spent 15 years ignored, then changed medicine during a pandemic.

Antibiotics Invention: Penicillin, Fleming, Florey, and Chain
Antibiotics began with penicillin's discovery, but turning mold into medicine required chemistry, fermentation, wartime scale-up, and clinical testing.

The Fleming Penicillin Discovery: How an Accident Changed Medicine
In 1928, Alexander Fleming noticed a mold dissolving bacteria on a contaminated plate. Here is the full story of the discovery, the 12-year gap before clinical use, and how it transformed medicine.

Alexander Fleming: The Messy Lab That Changed Medicine Forever
Alexander Fleming's life, discoveries, and verified quirks: the contaminated petri dish that became penicillin, painting with bacteria, and what Florey and Chain actually did.

The IUD — A History of the Intrauterine Device From Silkworm Gut to Hormonal Revolution
From Richard Richter's 1909 silkworm-gut ring to the Dalkon Shield disaster and Mirena's hormonal breakthrough, the IUD's story spans medicine, law, and reproductive rights.